# Tirzepatide vs Semaglutide: Major Adverse Liver Outcomes in Type 2 Diabetes A matched study found major adverse liver outcomes at 4.05 against 4.04 per 1,000 person-years for tirzepatide and semaglutide in adults with obesity and type 2 diabetes, hazard ratio 1.04. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/tirzepatide-vs-semaglutide-liver Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Tirzepatide vs Semaglutide: Major Adverse Liver Outcomes in Type 2 Diabetes In a matched analysis, tirzepatide and semaglutide showed nearly identical rates of major adverse liver outcomes. The reason to believe the null is that both beat a third drug in the same analysis. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Tirzepatide against semaglutide — liver outcomes · 1.0 · all patients · with fatty liver · as treated · Both drugs did beat sitagliptin — so the method can see a difference. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - New users of tirzepatide and injectable semaglutide, matched, followed a median of about 17 months. - Major adverse liver outcomes ran at 4.05 against 4.04 per 1000 person-years, hazard ratio 1.04, 95% CI 0.88 to 1.23. - The same null held among patients with fatty liver and in an as-treated analysis. - Both drugs did outperform sitagliptin in the study's own internal check. - Tirzepatide produced about 1.1 kg/m2 more reduction in body mass index, p < 0.001 — and no fewer liver events. Most of what makes this study worth reading is a check the authors ran on themselves. [Finding no difference](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes) has two explanations — there is not one, or the study could not have seen one — and almost nothing published bothers to separate them. ## What was compared Adults with overweight or obesity and type 2 diabetes starting tirzepatide or injectable semaglutide, drawn from a global research network and matched on baseline characteristics. [\[1\]](https://thisglp.com/research/tirzepatide-vs-semaglutide-liver#ref-1) The outcome was time to a first major adverse liver outcome: cirrhosis, a decompensating event, or liver cancer. This is a target trial emulation — an observational comparison built to behave like a trial, with eligibility and follow-up rules fixed in advance. It still does not randomize anyone. ## The result Over a median of roughly 17 months, incidence ran at 4.05 per 1000 person-years on tirzepatide and 4.04 on semaglutide — a hazard ratio of 1.04, 95% CI 0.88 to 1.23. Among patients with fatty liver the rates were 9.97 and 10.03 per 1000 person-years, hazard ratio 1.03, 95% CI 0.75 to 1.42. An as-treated analysis gave 0.98, 95% CI 0.80 to 1.21. Three ways of asking, three intervals sitting squarely across one. Why the sitagliptin check matters A study that cannot detect anything will report no difference between any two things you give it, and it will look identical to a study that found a real absence. So the authors ran both drugs against sitagliptin, where a difference is expected, and both significantly outperformed it. That does not prove the main comparison is right. It does establish that the data, the matching and the outcome definition are capable of producing a difference when one is there — which is the single thing most null results never demonstrate about themselves. ## More weight, same liver Tirzepatide achieved about 1.1 kg/m2 more reduction in body mass index, p < 0.001. It did not produce fewer liver events. Over seventeen months that is not a contradiction — it takes years for cirrhosis or liver cancer to arrive, and a difference in weight would have to work through a long causal chain to show up in those counts. It does sit alongside [the study where surgery lost more weight and improved liver stiffness no further](https://thisglp.com/research/semaglutide-vs-sleeve-liver-stiffness), and the two together make the weight-to-liver link look less automatic than it is usually described. ## What the window can carry Seventeen months is short for these endpoints and the authors say so, describing their conclusion as short- to medium-term. What the study supports is that neither drug is worse than the other on liver outcomes over that stretch. That is genuinely useful for anyone weighing the two, and it is not the same as either drug having been shown to prevent liver disease — a claim that needs [the trial evidence in that population](https://thisglp.com/research/semaglutide-and-liver-disease) and, for the approval that exists, [a fibrosis stage somebody has actually measured](https://thisglp.com/research/who-qualifies-for-semaglutide-for-liver-disease). ## Frequently asked Is one of these drugs better for the liver? Not over this window. Major adverse liver outcomes ran at 4.05 against 4.04 per 1000 person-years, with every sensitivity analysis giving an interval crossing one. Why should a null result be believed? Because the authors also compared both drugs against sitagliptin, where a difference was expected, and found one. That shows the method can detect a difference when it exists. Did the extra weight loss help? Tirzepatide produced about 1.1 kg/m2 more reduction in body mass index and no fewer liver events. Seventeen months is short for outcomes like cirrhosis and liver cancer. Was this a trial? No. It is a target trial emulation — an observational comparison with trial-like eligibility and follow-up rules set in advance — and nobody was randomized. ## Sources 1. \[1\] Banerjee M, et al. (2026). Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes Obesity. [PMID 42618523](https://pubmed.ncbi.nlm.nih.gov/42618523/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)